Navigation Links
Coronary imaging enhances ability to identify plaques likely to cause future heart disease
Date:1/20/2011

NEW YORK, NY JANUARY 20, 2011 Results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur.

The trial, Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT), is the first prospective natural history study of atherosclerosis using multi-modality imaging to characterize the coronary tree. The study findings were published in the January 20, 2011 issue of the New England Journal of Medicine.

"As a result of the PROSPECT trial, we are closer to being able to predictand therefore prevent sudden, unexpected adverse cardiac events," said principal investigator Gregg W. Stone, MD. Dr. Stone is Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation (CRF).

The multi-center trial studied 700 patients with acute coronary syndromes (ACS) using three-vessel multimodality intra-coronary imaging angiography, grayscale intravascular ultrasound (IVUS), and radiofrequency IVUS to quantify the clinical event rate due to atherosclerotic progression and to identify those lesions that place patients at risk for unexpected adverse cardiovascular events (sudden death, cardiac arrest, heart attacks and unstable or progressive angina).

Among the discoveries of the trial are that most untreated plaques that cause unexpected heart attacks are not mild lesions, as previously thought, but actually have a large plaque burden and/or a small lumen area. These are characteristics that were invisible to the coronary angiogram but easily identifiable by grayscale IVUS.

Moreover, and perhaps most importantly, for the first time it was demonstrated that characterization of the underlying plaque composition (with radiofrequency IVUS, also known as VH-IVUS) was able to significantly improve the ability to predict future adverse events beyond other more standard imaging techniques.

"These results mean that using a combination of imaging modalities, including IVUS to identify lesions with a large plaque burden and/or small lumen area, and VH-IVUS to identify a large necrotic core without a visible cap (a thin cap fibroatheroma) identifies the lesions that are at especially high risk of causing future adverse cardiovascular events," Dr. Stone said.

Results of the trial were first reported at the 2009 Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium, sponsored by CRF.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
646-434-4690
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. New research shows innovative respiratory stress test can quickly detect significant coronary artery disease in a noninvasive setting
2. Family history is strong predictor of obstructive coronary artery disease using CCTA
3. Mass. General Hospital to create registry for coronary optical coherence tomography
4. Coronary CTA a cost-effective alternative to cardiac catheterization for the evaluation of CAD
5. The Mount Sinai Hospital Earns Highest Ratings in New York State Report on Coronary Angioplasty
6. New research shows cardiologists can quickly detect significant coronary artery disease using a non-invasive simple, short respiratory stress test
7. Link established between erectile dysfunction and calcified coronary arteries
8. Carotid artery ultrasound is an effective alternative to more invasive coronary angiography
9. New tool to rule out coronary heart disease in primary care
10. Dietary Cocoa Flavanols Improve Vascular And Blood Pressure Measures For Coronary Artery Disease Patients
11. Lower-dose heparin use during coronary procedure does not appear to reduce risk of major bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
Breaking Medicine Technology: